16 September 2026 editorial review · Item
DFMO (eflornithine / TADPOL): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added DFMO/TADPOL entry. Checked 2023 publication including small dose groups, primary safety outcome, allergic withdrawal and secondary C-peptide signal; current Phase 2 status and actual 74 enrolment from registry. The early publication reports 31 drug+10 placebo; an older registry description retains 2:1 planned allocation.
- Primary sources checked: Inhibition of polyamine biosynthesis preserves beta-cell function in type 1 diabetes (peer-reviewed); NCT05594563 — study record (registry); NCT02384889 — study record (registry).
- Limits: The Phase 2 trial has no results. Regeneration category is explicitly explained as a grouping: no demonstrated human beta-cell regrowth. No extrapolation from oncology dosing or efficacy.